Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE) antibody construct blinatumomab as a potential therapy
Multi-agent chemotherapy is the standard treatment for most B cell malignancies. Since chemotherapy can be associated with significant toxicity and since relapses resistant to chemotherapy often develop, new therapies are needed. Blinatumomab (AMG 103 or MT103) is a late-stage candidate in clinical...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
January 2015
|
| In: |
International immunology
Year: 2015, Volume: 27, Issue: 1, Pages: 31-37 |
| ISSN: | 1460-2377 |
| DOI: | 10.1093/intimm/dxu089 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1093/intimm/dxu089 Verlag, Volltext: https://academic.oup.com/intimm/article/27/1/31/2950837 
|
| Author Notes: | Zachary Zimmerman, Tapan Maniar and Dirk Nagorsen |
| Summary: | Multi-agent chemotherapy is the standard treatment for most B cell malignancies. Since chemotherapy can be associated with significant toxicity and since relapses resistant to chemotherapy often develop, new therapies are needed. Blinatumomab (AMG 103 or MT103) is a late-stage candidate in clinical development, which belongs to a novel class of antibody constructs termed bi-specific T cell engager antibodies. This antibody construct has dual specificity for CD19 and CD3 and can re-direct polyclonal cytotoxic T lymphocytes toward the tumor. This review focuses on the pre-clinical and clinical development of blinatumomab as a powerful new tool in the treatment of B cell malignancies. |
|---|---|
| Item Description: | Gesehen am 19.11.2018 Advance access publication 19 September 2014 |
| Physical Description: | Online Resource |
| ISSN: | 1460-2377 |
| DOI: | 10.1093/intimm/dxu089 |